\n\n

Google hit with $1 billion fine for breaking EU antitrust rules

The European Union has fined Google’s parent company Alphabet €890 million (about $1 billion) for two separate violations of the bloc’s Digital Markets Act (DMA). One penalty is for giving its own products preferential treatment in search results, while the other is for blocking Android developers from sending users to alternate payment options.

A €460 million fine has been issued to Google for giving preferential treatment to its own Shopping, Hotels, and Flights services in Google Search results. The second €430 million penalty is for Play Store rules preventing developers from freely steering consumers to alternative payment systems that …

Read the full story at The Verge.

Related Posts

Facebook launches a dedicated Marketplace app for sellers, adds a free verification system

Seller is a dedicated Marketplace app for people who list and sell items frequently.

Robot snakes searched for Venezuela earthquake survivors in collapsed buildings

Robots slithered like snakes into the rubble of collapsed buildings to search for trapped survivors in the aftermath of Venezuela’s double earthquake disaster. The so-called snake robots represented a unique…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Four Palestinians and two Israelis killed in West Bank shooting

Four Palestinians and two Israelis killed in West Bank shooting

Five killed in occupied West Bank after Israeli settlers attack

Five killed in occupied West Bank after Israeli settlers attack

Indian student protests: What’s next after Modi’s promise on exam leaks?

Indian student protests: What’s next after Modi’s promise on exam leaks?

What to know about the White House Correspondents’ Dinner, take two

What to know about the White House Correspondents’ Dinner, take two

APOE2 may protect the brain from Alzheimer’s and aging

APOE2 may protect the brain from Alzheimer’s and aging

The billion-dollar problem keeping Ozempic, Wegovy, and Zepbound from patients

The billion-dollar problem keeping Ozempic, Wegovy, and Zepbound from patients